INTRODUCTION
Gliomas are the most common primary parenchymal brain tumors [1] . In 1928, Bailey and Cushing published the first systematic classification of gliomas on a histogenetic basis, meaning that morphological similarities of tumor cells with different glial cell types were employed to discriminate glioma entities for which a distinct histogenesis was assumed [2] . All subsequent classifications of gliomas, including the WHO classification of central nervous system tumors of 2007 [3] , similarly relied on the assessment of microscopic criteria for tumor typing and histological grading [3] . However, histological classification of gliomas is associated with considerable interobserver variability [4] . Recent studies using next-generation sequencing and microarray-based analyses have revealed characteristic genetic and epigenetic profiles in the various types of gliomas [5 && -8 && , 9, 10] . Molecular biomarkers have been identified that may refine tumor diagnostics and improve prediction of treatment response and outcome [11 & ]. Importantly, these molecular biomarkers can be detected in routinely formalin-fixed and paraffin-embedded (FFPE) material by means of widely available techniques such as immunohistochemistry, fluorescence in-situ hybridization (FISH) and DNA sequencing [12] [13] [14] [15] . The revised fourth edition of the WHO classification of tumors of the central nervous system 2016 [16 && ] has taken these developments into consideration and employs a new diagnostic concept that combines tumor histology and molecular genetics [17 & ,18 & ]. Histological tumor type, histological tumor grade À reflecting the tumor's malignancy À and molecular biomarkers are incorporated into an integrated diagnosis, for example 'diffuse astrocytoma, IDH-mutant, WHO grade II'.
WHO CLASSIFICATION 2016: INTEGRATED DIAGNOSTICS OF GLIOMAS
The inclusion of molecular biomarkers in the WHO classification 2016 of gliomas has markedly changed the classification of gliomas ( Fig. 1 ). Previously, astrocytic gliomas were separated from the oligodendroglial and mixed (oligoastrocytic) glioma groups [3] . Seminal findings about mutations affecting codon 132 of the IDH1 gene or codon 172 of the IDH2 gene (collectively referred to as IDH mutation) in gliomas indicated that IDH-mutant gliomas are biologically and clinically distinct from IDH-wildtype gliomas. Moreover, it was shown that astrocytic and oligodendroglial tumors -in addition to their infiltrative growth pattern -share frequent IDH mutations [19] [20] [21] . Therefore, the WHO classification 2016 lists all diffuse gliomas in one group called 'diffuse astrocytic and oligodendroglial tumors' [16 && ]. IDH-mutant oligodendroglial tumors differ from IDH-mutant astrocytic gliomas by the presence of whole-arm codeletions of 1p and 19q (1p/19q codeletion). The typical oligodendroglial cell morphology (so-called honeycomb cells with rounded nuclei, artificially swollen clear cytoplasm and prominent cell borders) is neither required nor sufficient for the diagnosis of an oligodendroglial tumor. Presence of combined IDH mutation and 1p/19q codeletion now constitutes the entitydefining criterion [16 && ,18 & ]. Moreover, based on molecular testing for IDH mutation and 1p/19q codeletion, mixed oligoastrocytic tumors (oligoastrocytomas, anaplastic oligoastrocytomas, and glioblastomas with oligodendroglial component) can be classified either as IDH-mutant and 1p/19q-codeleted oligodendroglial gliomas or as IDH-mutant or IDH-wildtype astrocytic gliomas [14,22 & ,23] . Therefore, classification of diffuse gliomas as oligoastrocytomas is no longer supported [16 && ]. Only in rare instances when molecular testing remains inconclusive and histology shows both astrocytic and oligodendroglial phenotypes, classification as oligoastrocytoma or anaplastic oligoastrocytoma, not otherwise specified (NOS), remains an option.
In addition to these conceptual changes, the new WHO classification includes three new glioma entities: 'diffuse midline glioma, H3-K27M-mutant', 'anaplastic pleomorphic astrocytoma', and 'ependymoma, RELA-fusion positive' [16 && ]. 'Epithelioid glioblastoma' is a new provisional variant of IDHwildtype glioblastoma ( Fig. 1 ). Diffuse midline glioma, H3-K27M-mutant, is defined by the presence of lysine-to-methionine missense mutations affecting codon 27 in either of the H3F3A, HIST1H3B, or HIST1H3C genes [16 && ,24,25] . These tumors arise predominantly in children and young adults, are located in midline structures, that is brain stem, thalamus, or spinal cord, and show an aggressive clinical behavior corresponding to WHO grade IV [16 && ]. Anaplastic pleomorphic astrocytoma, WHO grade III, is defined by histological features as a pleomorphic xanthoastrocytoma with five or more mitoses per 10 microscopic high power fields [ 
].
A few previous glioma variants, including fibrillary and protoplasmic astrocytoma as well as cellular ependymoma, have been deleted in the WHO classification 2016 ( Fig. 1 ). In addition, gliomatosis cerebri is no longer considered a distinct entity but a rare growth pattern that may occur in
KEY POINTS
The WHO classification 2016 introduces a novel integrated classification approach for gliomas that combines traditional histological criteria with assessment of molecular biomarkers.
We outline the new diagnostic approach ranging from histological examination of tissue sections to immunohistochemical and molecular analyses of relevant diagnostic biomarkers, including IDH mutation, 1p/19q codeletion, H3-K27M mutation, RELA fusion, and others.
We also discuss potential challenges of the new system caused by prolonged time and higher expenses for diagnostics, requirements for quality assurance, and the problem of tumors that cannot be conclusively tested for diagnostically relevant biomarkers.
PRACTICAL APPROACH TO INTEGRATED GLIOMA CLASSIFICATION

Histology
The routine procedure for glioma classification starts with the light microscopic evaluation of hematoxylin-eosin stained tissue sections ( Fig. 2 ). For rapid intraoperative diagnostics, cryostat sections cut from shock-frozen tissue specimens are used, whereas microscopic evaluation of FFPE tissue sections is required for definitive histological assessment. This usually allows for the discrimination of glial tumors from nonglial tumors and nonneoplastic, for example reactive or inflammatory lesions. Moreover, diffusely infiltrative astrocytic and oligodendroglial tumors II  II  II  II  III  III  III   IV   IV   IV   IV  IV  IV   IV   II  II  III  III  II  III   I  II  I  II  III   I  I  II   I   II  III   II   IV   IV   IV   III   III   I  II   II  II  II   II  I   III   II   II   II   II  II or III  III   II 
Immunohistochemistry
Microscopic analysis of gliomas additionally comprises a set of immunohistochemical stainings to substantiate the diagnosis and assess proliferative activity. Traditionally used immunohistochemical markers for gliomas include glial fibrillary acidic protein (GFAP), oligodendrocyte lineage transcription factor 2 (OLIG2), microtubule-associated protein 2 (MAP2), and epithelial membrane antigen (EMA), the latter often demonstrating a characteristic dot-or ring-like cytoplasmic positivity in ependymal tumors and angiocentric gliomas [16 && ]. Immunostaining for proliferation markers such as Ki-67 (MIB-1) highlights proliferative activity.
The WHO classification 2016 has extended the spectrum of diagnostically helpful immunostainings [32] . Notably, immunoreactivity with a mutation-specific antibody against the most common IDH1 mutation in gliomas, namely IDH1-R132H, allows for the identification of more than 90% of all IDH-mutant diffuse gliomas [13, 33] . Negative results of immunohistochemistry for IDH1-R132H do not, however, exclude an IDHmutant glioma as less frequent IDH1 or IDH2 mutations are not detected [13] . In this case, follow-up molecular analyses for other IDH mutations are required (Fig. 2) .
Immunohistochemical stainings for nuclear expression of ATRX and p53 help to subdivide IDH-mutant gliomas into diffuse astrocytic and oligodendroglial tumors [7 && ,14,15,32] . The majority of IDH-mutant astrocytic gliomas have lost nuclear ATRX immunoreactivity, whereas IDH-mutant and 1p/19q-codeleted oligodendroglial tumors invariably retain nuclear ATRX expression. Strong nuclear p53 positivity is frequent in IDH-mutant astrocytic gliomas but virtually never observed in IDH-mutant and 1p/19q-codeleted oligodendrogliomas that usually lack TP53 mutation [7 && ,8
&&
]. Most glioblastomas do not harbor IDH mutations, especially in elderly patients. Nuclear ATRX expression is retained in most but not all IDH-wildtype glioblastomas. For example, IDH-wildtype glioblastomas that carry a H3F3A-G34 histone 3.3 mutation frequently lack nuclear ATRX expression [15] . Approximately 40% of IDH-wildtype glioblastomas exhibit EGFR gene amplification and about half of these cases express the EGFRvIII deletion variant [34, 35] . Diffusely infiltrating gliomas located in midline structures should be immunohistochemically analyzed with antibodies against H3-K27M to exclude or confirm the diagnosis of a diffuse midline glioma, H3-K27M-mutant. These tumors additionally demonstrate loss of nuclear immunostaining for histone 3-trimethylated lysine 27, which further supports the diagnosis [36, 37] . Immunohistochemistry with a BRAF-V600E-specific antibody [38] may aid the classification of pleomorphic xanthoastrocytoma and epithelioid glioblastoma.
Molecular diagnostics
IDH mutation, H3-K27M mutation, 1p/19q codeletion, and C11orf95-RELA fusion are the four diagnostic biomarkers in the WHO classification 2016 of gliomas [16 && ,18 & ]. Molecular testing for IDH mutation is commonly performed by Sanger sequencing or pyrosequencing and is required in all instances of immunohistochemically IDH1-R132H-negative WHO grade II and III astrocytic and oligodendroglial tumors as well as all IDH1-R132H-negative glioblastomas occurring in patients before the age of 55 years or in patients with a lower grade precursor lesion [16 && ,18 & ]. A histologically classic glioblastoma that lacks IDH1-R132H immunoreactivity, has retained ATRX expression and occurs in a patient of 55 years or older can be assumed to be IDH-wildtype without sequencing [39] . Diffuse midline gliomas with H3-K27M mutation do not require IDH sequencing either. However, DNA sequencing for K27M mutations in H3F3A, HIST1H3B, or HIST1H3C may be necessary in IDH-wildtype diffuse midline gliomas with ambiguous immunostaining or negative immunoreactivity with an antibody against H3F3A-K27M only. All IDH-mutant gliomas demonstrating oligodendroglial or oligoastrocytic differentiation on histology and/or having retained nuclear ATRX expression must be tested for codeletion of 1p/19q. Most commonly, the 1p/19q codeletion status is determined by FISH, multiplex ligation-dependent probe amplification (MLPA), microsatellite analysis or microarray-based techniques [40] . If IDH mutation and 1p/19q codeletion are proven, the integrated diagnoses will be 'oligodendroglioma, IDH-mutant and 1p/19q-codeleted' or 'anaplastic oligodendroglioma, IDH-mutant and 1p/19qcodeleted', independent of the histological phenotype [16 && ,18 & ].
In IDH-wildtype gliomas confirmed by DNA sequencing, additional testing for 1p/19q codeletion is not required. Supratentorial ependymomas should be evaluated for C11orf95-RELA fusions, for example by FISH or reverse transcription-PCR, to discriminate RELA fusion-positive ependymomas from histologically similar tumors without this entity-defining marker.
Assessment of other biomarkers, for example TERT promoter mutation, BRAF-V600E mutation, or KIAA1549/BRAF-fusion, as well as determination of DNA mutation or DNA methylation profiles across multiple genes or CpG-sites may also facilitate glioma classification (for recent reviews, see refs. [40, 41] ). For example, TERT promoter mutations are frequent in IDH-wildtype glioblastomas as well as IDH-mutant and 1p/19q-codeleted oligodendrogliomas [42, 43] . BRAF-V600E mutations are found in the majority of pleomorphic xanthoastrocytomas and subsets of gangliogliomas, pilocytic astrocytomas, and IDH-wildtype glioblastomas (most commonly in the epithelioid variant) [26] [27] [28] , whereas KIAA1549/BRAF fusions are the most frequent alteration in pilocytic astrocytomas [44] .
MGMT promoter methylation does not guide diagnosis but is an important predictive biomarker for benefit from adjuvant chemotherapy with temozolomide (TMZ) [45] . In IDH-wildtype glioblastoma patients older than 65 years of age, who often cannot tolerate standard radiochemotherapy, MGMT promoter methylation may guide treatment decision between radiotherapy (in case of a MGMT promoterunmethylated tumor) versus chemotherapy with TMZ (in case of a MGMT promoter-methylated tumor) [46] . Recent data from the EORTC 26062-22061 phase III trial revealed that hypofractionated radiotherapy with concomitant and adjuvant TMZ improved survival in comparison to hypofractionated radiotherapy alone in elderly glioblastoma patients with MGMT promoter-methylated and with MGMT promoter-unmethylated tumors [47] . However, the survival benefit from the addition of TMZ to radiotherapy was more pronounced in patients with MGMT promoter-methylated tumors [47] .
New diagnostic approaches have been developed based on next-generation sequencing of glioma-tailored gene panels [48 & -51 & ]. Thereby, mutations and copy number aberrations of several molecular biomarkers can be simultaneously assessed, providing informative aberration profiles in a time-and cost-effective manner. Determination of tumor-specific DNA methylation and copy number profiles using microarray-based techniques applicable to DNA from FFPE samples also holds great promises for refined classification of brain tumors, including astrocytic and oligodendroglial gliomas, ependymomas, and others [8 && ,9,10,52,53] .
PRACTICAL IMPLICATIONS AND CHALLENGES OF INTEGRATED GLIOMA CLASSIFICATION
Demands for novel diagnostic testing methods and importance of quality assurance
If not already established, molecular testing methods allowing for the assessment of the aforementioned biomarkers need to be newly implemented in diagnostic laboratories. The WHO classification 2016 does not recommend specific methods [16 && ,18 & ]. However, laboratories need to have or should gain experience in the techniques they are using for clinical diagnostics [40] . Standard operating procedures and an internal quality control system need to be in place to ensure reliability of molecular testing. Measures to prevent contamination, for example separated pre-and post-PCR laboratories, and procedures to avoid sample mix-up leading to false-positive and falsenegative results are required. In addition, external quality assessments, for example in the form of interlaboratory trials and/or reference laboratories, need to be organized to assure reliability of molecular testing results across different laboratories.
Challenges caused by 'not otherwise specified' diagnoses
Although integrated classification clearly sharpens diagnostic accuracy, gliomas that cannot be conclusively assessed by molecular tests are a challenge [16 && ,18 & ]. These NOS tumors pose problems because they suffer from diagnostic uncertainty and interobserver variability [4] . Certain NOS categories in fact represent 'diagnostic wastebaskets' (e.g. oligoastrocytoma, NOS) that are composed of biologically and clinically distinct entities. As treatment is increasingly tailored according to integrated diagnoses and specific molecular marker profiles, planning of the optimal postsurgical treatment regimen for NOS glioma patients may be challenging. Moreover, molecular characterization of gliomas is becoming a prerequisite for clinical trials and individually tailored therapies. As NOS glioma patients may not be eligible for biomarker-based therapy trials and novel targeted therapies, all possible efforts should be undertaken to achieve an integrated diagnosis for each glioma patient.
Prolonged time to integrated diagnosis
The WHO classification 2007 -based on histology alone -allowed for a final pathology report within a few days after operation. Integrated classification according to the WHO classification 2016 may prolong the time to conclusive diagnosis when additional molecular tests are required. Some biomarkers, e.g. IDH1-R132H mutation, loss of nuclear ATRX expression, and H3-K27M mutation, are detectable by immunohistochemistry [32] and therefore do not prolong time to diagnosis. However, if additional molecular (cyto)genetic tests are necessary, the diagnostic procedure often takes more than a week. Additional delays may result from a multistep approach (e.g. low-grade glioma ! IDH-R132H negative ! IDH1 and IDH2 wildtype ! BRAF-fusion?) or from the fact that samples need to be sent out to external laboratories for molecular tests. In addition, it may be reasonable to collect cases for a test that is not performed on a daily basis to save expenses and reduce laboratory workload. All in all, the assessment of molecular biomarkers takes longer than simple histological and immunohistochemical stainings. Follow-up pathology reports detailing molecular test results and the corresponding integrated diagnosis are becoming common practice. However, this should not lead to a delay in postsurgical treatment. Thus, reliable logistics must be established to ensure that patients and their treating physicians receive the final pathology report as soon as possible, even when the patient has already been referred to an outside institution.
Increased costs for molecular diagnostics
Calculations of the costs caused by the integration of molecular diagnostics into routine classification are difficult and depend on the number and types of assays that are being used. Needless to say, the new approach increases the workload for laboratory personnel and the expenses for consumables, and these higher costs may pose a challenge to the healthcare system. In fact, the issue of reimbursement of molecular tests required for WHO classification 2016 is still unresolved in many countries. However, the obvious benefits for both patients and physicians provided by the more precise and objective classification clearly outweigh the increased costs, and reimbursement regulations must be established in due time.
CONCLUSION
The WHO classification 2016 combines histological information and molecular biomarkers to establish integrated glioma diagnoses. Novel glioma entities have been defined by specific genetic alterations, such as diffuse midline glioma, H3-K27M-mutant, and ependymoma, RELA fusion-positive. Thus, contemporary glioma diagnostics involves conventional histological evaluation as well as ancillary immunohistochemical stainings and molecular (cyto)genetic tests for a defined set of biomarkers. This approach allows for a more precise and reproducible diagnostic stratification of gliomas into biologically and prognostically meaningful entities. In addition, assessment of predictive biomarkers like MGMT promoter methylation is important for therapeutic decision-making, for example in elderly patients with IDH-wildtype glioblastoma. Increased expenses, prolonged time to diagnosis, requirements for quality assurance of molecular tests, and the problem of NOS diagnosis are potential challenges of the new classification system. Moreover, a need for regular updates of the classification system is foreseeable because of rapid advancements in high-throughput analytical techniques and the identification of novel biomarkers.
